12/19
10:07 am
lly
Eli Lilly and Company (NYSE:LLY) had its "outperform" rating reaffirmed by analysts at Sanford C. Bernstein.
Low
Report
Eli Lilly and Company (NYSE:LLY) had its "outperform" rating reaffirmed by analysts at Sanford C. Bernstein.
12/18
03:03 pm
lly
Eli Lilly and Company (NYSE:LLY) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
Low
Report
Eli Lilly and Company (NYSE:LLY) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
12/18
12:03 pm
lly
Eli Lilly and Company (NYSE:LLY) had its "neutral" rating reaffirmed by analysts at UBS Group AG.
Low
Report
Eli Lilly and Company (NYSE:LLY) had its "neutral" rating reaffirmed by analysts at UBS Group AG.
12/16
05:31 am
lly
Eli Lilly upgraded to Buy from Neutral at Daiwa
Low
Report
Eli Lilly upgraded to Buy from Neutral at Daiwa
12/10
03:10 pm
lly
Rating for LLY
Low
Report
Rating for LLY
12/10
03:10 pm
lly
Rating for LLY
Low
Report
Rating for LLY
12/10
07:21 am
lly
Eli Lilly and Company (NYSE:LLY) had its "hold" rating reaffirmed by analysts at HSBC Holdings plc.
Low
Report
Eli Lilly and Company (NYSE:LLY) had its "hold" rating reaffirmed by analysts at HSBC Holdings plc.
12/4
08:59 am
lly
Rating for LLY
Low
Report
Rating for LLY
12/4
08:59 am
lly
Rating for LLY
Low
Report
Rating for LLY
12/3
08:05 am
lly
Eli Lilly and Company (NYSE:LLY) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
Eli Lilly and Company (NYSE:LLY) had its "buy" rating reaffirmed by analysts at Guggenheim.
12/3
08:05 am
lly
Eli Lilly and Company (NYSE:LLY) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
Eli Lilly and Company (NYSE:LLY) had its "buy" rating reaffirmed by analysts at Guggenheim.
12/2
11:13 am
lly
Eli Lilly and Company (NYSE:LLY) had its "outperform" rating reaffirmed by analysts at BMO Capital Markets.
Low
Report
Eli Lilly and Company (NYSE:LLY) had its "outperform" rating reaffirmed by analysts at BMO Capital Markets.
12/1
11:04 am
lly
Eli Lilly and Company (NYSE:LLY) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Low
Report
Eli Lilly and Company (NYSE:LLY) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
11/24
11:18 am
lly
Rating for LLY
Low
Report
Rating for LLY
11/24
11:18 am
lly
Rating for LLY
Low
Report
Rating for LLY
11/24
10:06 am
lly
Rating for LLY
Low
Report
Rating for LLY
11/24
10:06 am
lly
Rating for LLY
Low
Report
Rating for LLY
11/24
07:20 am
lly
Eli Lilly and Company (NYSE:LLY) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Low
Report
Eli Lilly and Company (NYSE:LLY) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
11/24
07:20 am
lly
Eli Lilly and Company (NYSE:LLY) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Low
Report
Eli Lilly and Company (NYSE:LLY) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
11/24
07:19 am
lly
Eli Lilly and Company (NYSE:LLY) had its "outperform" rating reaffirmed by analysts at Sanford C. Bernstein.
Low
Report
Eli Lilly and Company (NYSE:LLY) had its "outperform" rating reaffirmed by analysts at Sanford C. Bernstein.
11/18
10:33 am
lly
Rating for LLY
Low
Report
Rating for LLY
11/14
07:52 am
lly
Eli Lilly and Company (NYSE:LLY) was upgraded by analysts at Scotiabank to a "strong-buy" rating.
Low
Report
Eli Lilly and Company (NYSE:LLY) was upgraded by analysts at Scotiabank to a "strong-buy" rating.
11/14
07:52 am
lly
Eli Lilly and Company (NYSE:LLY) was upgraded by analysts at Scotiabank to a "strong-buy" rating.
Low
Report
Eli Lilly and Company (NYSE:LLY) was upgraded by analysts at Scotiabank to a "strong-buy" rating.
11/13
09:53 am
lly
Eli Lilly and Company (NYSE:LLY) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $1,165.00 price target on the stock.
Low
Report
Eli Lilly and Company (NYSE:LLY) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $1,165.00 price target on the stock.
11/13
09:53 am
lly
Eli Lilly and Company (NYSE:LLY) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $1,165.00 price target on the stock.
Low
Report
Eli Lilly and Company (NYSE:LLY) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $1,165.00 price target on the stock.